Comparative Study on the Effectiveness of Antifungal Agents in Different Regimens against Vaginal Candidiasis

Mikamo, Hiroshige; Kawazoe, Kyoko; Sato, Yasumasa; Hayasaki, Yoh; Tamaya, Teruhiko

doi:10.1159/000007136

Cited by 23 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of C. albicans as a pathogen in this study is consistent with findings in the literature [1,3,4,12]; but there is also an increasing trend of non-albicans species as a cause of fungal infection [6,11,13]. Among these species, C. glabrate, C. tropicalis and C. parapsilosis appear to be commonly detected [1,3,4,[12][13][14].…”

Section: Discussionsupporting

confidence: 88%

“…In our previous study, we noted that the detection rate of non-albicans Candida species has been increasing in recent years [14].…”

Section: Discussionmentioning

confidence: 97%

“…It was less effective against C. glabrata and C. krusei, while a high minimal Mikamo/Sato/Hayasaki/Tamaya inhibitory concentration does not necessarily predict clinical failure [14]. Fluconazole is effective against non-albicans candidal infections at the rate of 77% [13], and against infections caused by C. parapsilosis and C. tropicalis, whereas C. glabrate is dose-dependently responsive to fluconazole.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Current Status and Fluconazole Treatment of Pelvic Fungal Gynecological Infections

Mikamo

Sato²,

Hayasaki³

et al. 2000

Chemotherapy

Self Cite

View full text Add to dashboard Cite

The incidence of opportunistic fungal infections has recently been increasing in many clinical fields. Fluconazole is commonly used against systemic fungal infections. The present study was undertaken to investigate the current status and the efficacy of fluconazole in pelvic fungal gynecological infections. Thirty-eight patients aged 36–72 years old diagnosed with pelvic peritonitis with positive fungal culture in pelvic ascites were enrolled in this study and given fluconazole treatment. Forty-two pathogens were isolated from the 38 assessable patients. The predominant pathogen was Candida albicans with an incidence of 61.9% (26/42). Others included non-albicans Candida species amounting to 38.1% (16/42): 19.0% (8/42) Candida glabrata, 7.1% (3/42) Candida tropicalis, 7.1% (3/42) Candida parapsilosis and 4.8% (2/42) Candida krusei. The clinical cure rate at the end of fluconazole treatment was assessed as 30/38 (78.9%), and the fungal eradication rate as 26/42 (61.9%). Each rate was 29/38 (76.3%) and 26/42 (61.9%), respectively, at 1 week after the treatment, while the eradication rate of C. albicans and non-albicans species was 20/26 (76.9%) and 6/16 (37.5%), respectively. There was no adverse effect exept for slight elevations of GOT, GPT and LDH observed in 1 patient (2.6%), which returned to normal after the treatment. It seems there may be an increasing trend of non-albicans species in pelvic fungal gynecological infection, against which fluconazole appears to be rather effective.

show abstract

Section: Discussionsupporting

confidence: 88%

“…In our previous study, we noted that the detection rate of non-albicans Candida species has been increasing in recent years [14].…”

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current Status and Fluconazole Treatment of Pelvic Fungal Gynecological Infections

Mikamo

Sato²,

Hayasaki³

et al. 2000

Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…13 The Clinical cure rate was significantly high in the itraconazole group compared to the fluconazole group. Results of these studies are similar to our study results.…”

Section: Discussionmentioning

confidence: 87%

Efficacy of Itraconazole Versus Fluconazole in Vulvovaginal Candidiasis: An in Vivo Study

Tolasaria¹,

Nandi²

2014

jemds

View full text Add to dashboard Cite

AIMS:To compare the efficacy of itraconazole 200mg twice for one day and fluconazole 150mg single dose in the treatment of acute vulvovaginal candidiasis. METHODS: The study was carried out at the Department of Obstetrics & Gynaecology, K.P.C. Medical College & Hospital, Jadavpur, Kolkata, from August 2011 to July 2012 on 80 women with clinical and mycological diagnosis of vulvovaginal candidiasis. Diagnosis was based on history, clinical examination and relevant investigations. The women were divided into two equal groups. After initial assessment, Group 1 was treated with capsule itraconazole 200mg twice for one day, and Group 2 with capsule fluconazole 150mg single dose. They were assessed clinically for cure and relapse on day 7 and 21 respectively. RESULTS: The overall clinical evaluation showed 70% (n=28) cure rate with itraconazole and 50% (n=20) with fluconazole. In Group-1, 9 (22.5%) and in Group-2, 10 (25%) showed some improvement, while 3 (7.5%) in Group 1, and 10 (25%) in Group 2 failed to respond. At the 7th day follow up, Clinical success rates (cure and improvement) were 92.5% in the itraconazole group and 75% in the fluconazole group (P <0.05). Relapse was observed in 5 (18%) and 8 (40%) of the cured cases in Group 1 and Group 2 respectively on day 21. CONCLUSION: Itraconazole was found to be more effective in the treatment of vulvovaginal candidiasis compared to fluconazole with high cure and low relapse rate.

show abstract

“…Forms of infectious vaginitis sustained by mixed micro-organisms are also observed frequently [6] . Vaginal infections can be successfully treated by using one or more pathogen-specific antimicrobials [1,3,[7][8][9] , but, before vaginitis is treated, the cause must be ascertained by using appropriate laboratory tests [1,2,6,7,10] . Because some strains of Candida albicans resistant to topical azole antifungals [3,11] and strains of Trichomonas vaginalis resistant to treatment with metronidazole and tinidazole [12][13][14] have been recently isolated, it is also necessary to verify the susceptibility of micro-organisms to the recommended antimicrobials in certain cases [3] .…”

Section: Introductionmentioning

confidence: 99%

Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin

Tirri¹,

Bitzer²,

Geudelin³

et al. 2010

Chemotherapy

View full text Add to dashboard Cite

Background/Aims: Intravaginal pentamycin is a polyene macrolide with a broad spectrum of antimicrobial activity and is effective in various forms of infectious vaginitis. We evaluated the safety, tolerability and pharmacokinetics of escalating doses of this product. Methods: Nineteen healthy volunteers were randomized to receive double blind one of five doses of intravaginal pentamycin (3, 10, 30, 60 or 100 mg) or the corresponding dose of pentamycin vehicle daily for 6 days. Patients with symptomatic vaginitis received a single dose of 60 (n = 6) or 100 mg (n = 6) of intravaginal pentamycin. Safety and tolerability parameters were monitored throughout the study. Plasma concentrations of pentamycin were measured daily in the healthy volunteers and on the day of drug application in the patients. Results: The most frequently reported adverse events were mild or moderate vaginal discharge and mild symptoms of vaginal irritation (mainly pruritus or burning sensation), which also occurred in women who applied the vehicle. No patient with symptomatic vaginitis reported treatment-related adverse events. The plasma levels of pentamycin were below the quantification limit in all samples. Conclusion: Intravaginal pentamycin does not cause adverse reactions compared with vehicle and is not absorbed through the intact or the inflamed vagina.

show abstract

Comparative Study on the Effectiveness of Antifungal Agents in Different Regimens against Vaginal Candidiasis

Cited by 23 publications

References 12 publications

Current Status and Fluconazole Treatment of Pelvic Fungal Gynecological Infections

Current Status and Fluconazole Treatment of Pelvic Fungal Gynecological Infections

Efficacy of Itraconazole Versus Fluconazole in Vulvovaginal Candidiasis: An in Vivo Study

Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin

Contact Info

Product

Resources

About